Management of Post-Cardiac Injury Syndrome (PCIS) with Antiplatelet and Anti-Inflammatory Therapy

Antiplatelet Management During PCIS Treatment

The American Heart Association recommends dual antiplatelet therapy with aspirin 81 mg daily plus a P2Y12 inhibitor (ticagrelor 90 mg twice daily or prasugrel 10 mg daily preferred over clopidogrel 75 mg daily) should be continued for at least 12 months after PCI, even during PCIS treatment 1, 2
After PCI for acute coronary syndromes, DAPT must continue for a minimum of 12 months regardless of stent type 3, 1
For non-ACS indications with drug-eluting stents, DAPT should continue for at least 12 months if bleeding risk is not prohibitive 2
Aspirin 81 mg daily is preferred over higher doses to minimize bleeding risk 3, 2
Consider shortening DAPT duration to <12 months only if bleeding morbidity clearly outweighs ischemic benefit 3, 2
Transition to ticagrelor monotherapy ≥1 month after PCI is reasonable in patients who have tolerated initial DAPT 1
Add proton pump inhibitor (avoid omeprazole/esomeprazole with clopidogrel due to CYP2C19 interaction) for gastrointestinal protection 1, 4

Monitor for bleeding complications (hematemesis, melena, hematuria, excessive bruising) from the combination of anti-inflammatory therapy and DAPT 5
Complete blood count to detect occult bleeding manifesting as anemia 5

Do not discontinue DAPT prematurely due to PCIS diagnosis, as stent thrombosis risk (leading to MI, cardiogenic shock, and death) far outweighs the bleeding risk in most cases 4